Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term
New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken
From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine
From fibremaxxing and longevity clinics to GLP-1 drugs, AI hospitals and workplace mental health, 2025 reshaped how India talks about prevention, ageing and wellbeing
As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities
A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect
From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions
Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies
